Adaptive proton therapy pediatric solid tumors Hodgkin's lymphoma

A new clinical trial registration entry was added to ClinicalTrials.gov documenting a Phase 2 study on adaptive proton therapy for pediatric solid tumors and Hodgkin's lymphoma. The trial will evaluate treatment efficacy and safety parameters in approximately 40 pediatric patients.

For clinical investigators and healthcare providers, this represents an additional ongoing research option for pediatric oncology patients. The registration fulfills sponsor obligations under FDAAA 801 for clinical trial disclosure requirements.